Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (10606)	7/2/1999 9:42:00 AM
From: aknahow	Respond to of 17367

True, the devil you know.... If they do a deal with Pfizer or Bristo, Rick Harmon, wont be very impressed as i gater he does not think that much of either. But perhaps Mr. Market will be kinder. Bristol with its' new found interest in A.I.D.S. might have more of an interest.

To: Tharos who wrote (10606)	7/2/1999 10:21:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

From your area of interest. Note interest in inflammation aids. "Kissei was founded in 1946 and has grown into one of Japan's leading pharmaceutical companies. Kissei's emphasis is on the research and development of original drugs having the potential to be widely accepted in the world market. The company has been successfully developing promising new drugs including those for dysuria, diabetes, and prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA). Kissei also continues to collaborate with Vertex on the development of VX-745, a p38 MAP kinase inhibitor for the treatment of inflammatory diseases." From press release issued today.